Subcutaneous methylnaltrexone for treatment of acute opioid-induced constipation: Phase 2 study in rehabilitation after orthopedic surgery

Journal of Hospital Medicine

Volumn 7, Issue 2, 2012, Pages 67-72

  Anissian, Lucas ^a   Schwartz, Harry W ^b   Vincent, Kevin ^c   Vincent, Heather K ^c   Carpenito, Jennifer ^d   Stambler, Nancy ^d   Ramakrishna, Tage ^d  

^a Louisiana State University School of Medicine Shreveport   (United States)

^b MOSS REHABILITATION RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d A Subsidiary of Lantheus Holdings   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 METHYLNALTREXONE; OPIATE; PLACEBO;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ABDOMINAL PAIN; ABDOMINAL TENDERNESS; ADULT; ANEMIA; ARTICLE; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FRACTURE REDUCTION; HEADACHE; HUMAN; HYPOTENSION; JOINT SWELLING; MALE; MULTICENTER STUDY; NAUSEA; OPIOID INDUCED CONSTIPATION; ORTHOPEDIC SURGERY; PAIN; PAIN ASSESSMENT; PARALLEL DESIGN; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE ANALGESIA; POSTOPERATIVE PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REHABILITATION CARE; SKIN ULCER; SOMNOLENCE; SPINE FUSION; SURGICAL PATIENT; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; TREATMENT DURATION; TREATMENT WITHDRAWAL; URINARY TRACT INFECTION; WITHDRAWAL SYNDROME; WOUND INFECTION;

AGED; ANALGESICS, OPIOID; CONSTIPATION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; ORTHOPEDIC PROCEDURES; PILOT PROJECTS; QUATERNARY AMMONIUM COMPOUNDS; REHABILITATION; TREATMENT OUTCOME;

EID: 84856633122     PISSN: 15535592     EISSN: 15535606     Source Type: Journal    
DOI: 10.1002/jhm.943     Document Type: Article

References (22)

1. Jain S, Datta S. Postoperative pain management. Chest Surg Clin N Am. 1997; 7: 773-799.
2. Diaz G, Flood P. Strategies for effective postoperative pain management. Minerva Anestesiol. 2006; 72: 145-150.
3. Bates JJ, Foss JF, Murphy DB. Are peripheral opioid antagonists the solution to opioid side effects? Anesth Analg. 2004; 98: 116-122.
4. Petersen-Felix S, Curatolo M. Neuroplasticity-an important factor in acute and chronic pain. Swiss Med Wkly. 2002; 132: 273-278.
5. Stephens J, Laskin B, Pashos C, Pena B, Wong J. The burden of acute postoperative pain and the potential role of the COX-2-specific inhibitors. Rheumatology (Oxford). 2003; 42( suppl 3): iii40-iii52.
6. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg. 2001; 182( suppl 5A): 11S-18S.
7. Swegle JM, Logemann C. Management of common opioid-induced adverse effects. Am Fam Physician. 2006; 74: 1347-1354.
8. Yuan CS, Foss JF. Antagonism of gastrointestinal opioid effects. Reg Anesth Pain Med. 2000; 25: 639-642.
9. Yuan CS. Methylnaltrexone mechanisms of action and effects on opioid bowel dysfunction and other opioid adverse effects. Ann Pharmacother. 2007; 41: 984-993.
10. Yuan CS, Foss JF. Methylnaltrexone: investigation of clinical applications. Drug Dev Res. 2000; 50: 133-141.
11. Murphy DB, Sutton JA, Prescott LF, Murphy MB. Opioid-induced delay in gastric emptying: a peripheral mechanism in humans. Anesthesiology. 1997; 87: 765-770.
12. Yuan CS, Foss JF, O'Connor M, et al. Effects of enteric-coated methylnaltrexone in preventing opioid-induced delay in oral-cecal transit time. Clin Pharmacol Ther. 2000; 67: 398-404.
13. Yuan CS, Foss JF, O'Connor M, Toledano A, Roizen MF, Moss J. Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind randomized placebo-controlled trial. Clin Pharmacol Ther. 1996; 59: 469-475.
14. Yuan CS, Foss JF, O'Connor M, Osinski J, Roizen MF, Moss J. Effects of intravenous methylnaltrexone on opioid-induced gut motility and transit time changes in subjects receiving chronic methadone therapy: a pilot study. Pain. 1999; 83: 631-635.
15. Yuan CS, Foss JF, O'Connor M, et al. Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial. JAMA. 2000; 283: 367-372.
16. Yuan CS, Foss JF. Oral methylnaltrexone for opioid-induced constipation. JAMA. 2000; 284: 1383-1384.
17. Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008; 328: 2332-2343.
18. Slatkin N, Thomas J, Lipman AG, et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. J Support Oncol. 2009; 7: 39-46.
19. Relistor [package insert]. Philadelphia, PA, and Tarrytown, NY: Wyeth Pharmaceuticals Inc and Progenics Pharmaceuticals; 2009.
20. Michna E, Blonsky ER, Schulman S, et al. Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study. J Pain. 2011; 12: 554-562.
21. Handelsman L, Cochrane KJ, Aronson MJ, Ness R, Rubinstein KJ, Kanof PD. Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse. 1987; 13: 293-308.
22. Chamberlain BH, Cross K, Winston JL, et al. Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness. J Pain Symptom Manage. 2009; 38: 683-690.